Samaritan and Georgetown University Expand Collaboration.Business Editors/Health/Medical Writers LAS VEGAS--(BUSINESS WIRE)--Feb. 9, 2004 Samaritan Pharmaceuticals Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :SPHC) and Samaritan Research Labs, Georgetown University Georgetown University, in the Georgetown section of Washington, D.C.; Jesuit; coeducational; founded 1789 by John Carroll, chartered 1815, inc. 1844. Its law and medical schools are noteworthy, and its archives are especially rich in letters and manuscripts by and today announced that, Samaritan and Georgetown University, have expanded their strategic alliance collaboration, to increase the growing value of its strategic alliance, and give Samaritan a continually con·tin·u·al adj. 1. Recurring regularly or frequently: the continual need to pay the mortgage. 2. expanding pipeline. Samaritan is a product driven company and has carefully built its therapeutic area expertise around a deep pipeline model. Samaritan's strategy for long-term sustained growth is to methodically me·thod·i·cal also me·thod·ic adj. 1. Arranged or proceeding in regular, systematic order. 2. Characterized by ordered and systematic habits or behavior. See Synonyms at orderly. build a steady flow of quality drug candidates. Dr. Janet Greeson, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Samaritan Pharmaceuticals stated, "We are extremely pleased to expand our successful relationship with Georgetown University and feel grateful to have Samaritan Laboratory scientists that are committed to our shared goals and our passion to succeed." Samaritan will increase its funding commitment under this collaboration; expand the scope of development in the core areas of AIDS, Alzheimer's, Cancer and Cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease ; and will continue to have first right of refusal to exclusively license the results. Georgetown University will receive additional funding to hire more researchers to support the expansion; and the funding for the collaboration was extended for an additional five years to 2013. Dr. Greeson, further stated, "We view this expanded collaboration as a strong endorsement of our approach of bringing innovative bench science to a patient's bedside. We have a number of very important breakthroughs in each of our core therapeutic areas, which could not only benefit patients with these dreadful diseases but could possibly add substantial long term value to Samaritan if approved."
To Date the Samaritan and Georgetown University Collaboration Has
Produced Numerous Publications and Patent Applications Validating
the Science:
Publications in peer-reviewed journals:
1. Xu, J, Lecanu L, Han Z, Yao Z, Greeson J, Papadopoulos V
(2003)
Inhibition of adrenal cortical steroid formation by procaine
is mediated by reduction of the cAMP-induced
3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger
ribonucleic acid.
J Pharmacology & Experimental Therapeutics, 307:1148-1157.
2. Lecanu L, Yao W, Teper GL, Yao ZX, Greeson J, Papadopoulos V
(2004)
Identification of naturally occurring spirostenols preventing
(beta)-amyloid-induced neurotoxicity,
Steroids, 69:1-16.
3. Diallo S, Lecanu L, Greeson J, Papadopoulos V (2004)
A capillary gas chromatography/mass spectrometric method for
the quantification of hydroxysteroids in human plasma.
Analytical Biochemistry, 324:123-130.
Patent applications and exclusively licensed technologies as a
result of collaboration:
1. Yao Z, Greeson J, Papadopoulos V (2002)
Components and methods for reducing (beta)-amyloid-induced
cytotoxicity and therapies based thereon.
2. Lecanu L, Greeson J, Papadopoulos V (2003)
Neuroprotective spirostenol pharmaceutical compositions.
3. Yao Z, Lecanu L, Teper G, Greeson J, Papadopoulos V (2003)
Neuroprotective spirostenol pharmaceutical compositions.
4. Lecanu L, Greeson J, Papadopoulos V (2003)
Animal model simulating neurologic disease.
5. Xu J, Lecanu L, Greeson J, Papadopoulos V (2003)
Methods and compositions for modulating serum cortisol levels.
6. Lecanu L, Greeson J, Papadopoulos V (2003)
Novel sigma-1 receptor ligand with acetylcholinesterase
inhibition properties.
7. Lecanu L, Greeson J, Papadopoulos V (2003)
Components, extracts and methods for reducing
(beta)-amyloid-induced cytotoxicity and therapies based
thereon based on procaine and procaine derivatives.
In Addition, Samaritan Pharmaceuticals Exclusively Licensed and is
Developing the Following Technologies from Georgetown U.:
1. U.S. Patent Application entitled, "Peripheral-type
Benzodiazepine Receptor: A Tool for Detection, Diagnosis,
Prognosis, and Treatment of Human Breast Cancer."
2. U.S. Provisional Patent entitled, "Peripheral-Type
Benzodiazepine Receptor Associated Proteins, Cloning,
Expression and Methods of Use."
3. U.S. Provisional Patent Application entitled, "Cholesterol
Recognition Sequence."
4. U.S. Provisional Patent Application entitled, "Neurosteroids
As Markers for Alzheimer's Disease."
Why University Industry Research Relationships Are Important "Many early stage university technologies need a 'champion' for successful transfer and would languish but for the focused efforts of companies. In summary, university industry research collaboration has contributed and will continue to contribute significantly to national competitiveness as well as the intellectual vitality vi·tal·i·ty n. 1. The capacity to live, grow, or develop. 2. Physical or intellectual vigor; energy. of universities and the economic health of industry," states the Council on Governmental Relations. http://www.princeton.edu/~seasplan/links/A%20review%20of %20University%20Industry%20Research%20Relationships%20-%20COGR COGR Council on Governmental Relations COGR Common Grackle (bird species) .htm (Photo: http://www.newscom.com/cgi-bin/prnh/20030129/SPHCLOGO) About Samaritan Pharma: "A Little Bridge Can Go a Long Way" Samaritan Pharmaceuticals bridges University bright ideas through drug development thereby creating a path for promising new drugs to become commercially viable products. Currently, Samaritan is advancing its late stage HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. Immuno-therapeutic drug with antiviral antiviral /an·ti·vi·ral/ (-vi´ral) destroying viruses or suppressing their replication, or an agent that so acts. an·ti·vi·ral adj. properties through regulatory affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trials in 2004. At the same time, in collaboration with Georgetown University, Samaritan is advancing a growing pipeline of drugs for AIDS, Alzheimer's, and Cardiovascular disease through preclinical trials Noun 1. preclinical trial - a laboratory test of a new drug or a new invasive medical device on animal subjects; conducted to gather evidence justifying a clinical trial preclinical phase, preclinical test in preparation for future growth. Disclaimer (networking) disclaimer - Statement ritually appended to many Usenet postings (sometimes automatically, by the posting software) reiterating the fact (which should be obvious, but is easily forgotten) that the article reflects its author's opinions and not necessarily those of the The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. filed May 15, 2003. The company undertakes no duty to update forward-looking statements. Samaritan Pharmaceuticals, Inc. 702/735-7001, Fax 702/737-7016 Gene Boyle, Business Development Email: GeneBoyle@aol.com To receive future press releases and newsletters automatically, or for more information, visit our Web site www.samaritanpharmaceuticals.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion